In biopharmaceutical development, the long-standing practice of uniformly relying on large comparative clinical trials in patients is weakening, while review systems that place greater emphasis on precise analysis and pharmacokinetic data are spreading. In Korea, biosimilars that meet certain requirements can be exempted from submitting Phase 3 clinical trial data, and approval and review timelines are also being shortened. At the same time, the trend toward reducing animal testing is entering the regulatory mainstream. China’s regulatory authorities, through the PIONEER program, have officially designated alternative evaluation methods such as organoids, organ-on-a-chip systems, and simulations, showing that the very format of nonclinical data is changing.

In the market for health-related products, there is a growing trend toward more direct scrutiny of the quality of the evidence used to explain them, rather than just the ingredients or devices themselves. The accuracy controversy in the United States surrounding the Oura Ring, which has officially announced its entry into Korea, shows that wearables have entered a stage where they are expected to offer medical-grade reliability, while also prompting closer examination of the gap between claims such as 95% accuracy and the actual methods used to verify them. In the same context, the government is also moving toward rechecking even previously recognized functional claims over time. The reevaluation of 10 health functional food ingredients means that once-approved functionality is not effectively a permanent license, and suggests that to maintain consumer trust, labeling and intake standards may continue to be adjusted in line with the latest evidence.

Regional research institutes and local governments have stepped up efforts to ensure that natural-product-based materials do not remain confined to research on local specialties, but instead connect to overseas networks and lead to commercialization and exports. Namwon expanded its route into the Middle East through cooperation with the UAE’s Sharjah Research, Technology and Innovation Park (SRTIP), while Jinan is seeking to broaden the uses of red ginseng in the European wellness and beauty market through exchanges with a Vatican monastery. Behind this trend is the view that discovering materials alone yields limited results for regional industry. Joint development between the Jeonnam Bioindustry Foundation and private companies, along with the use of industry platforms such as CPHI KOREA, represents an effort to extend research infrastructure all the way to actual products and buyer connections, showing that regional biotech is moving from a research-centered stage to a market-linked one...

Fashion platforms and beauty brands used large-scale offline events not merely for promotion but as tools to drive sales conversion. In Musinsa’s case, more than 31,000 people visited its Seongsu event, and online transaction value jumped 246% from a year earlier, showing how on-site experiences translated directly into increased online purchases. This trend has expanded beyond individual companies to city-level events as well. In programs linked to Seoul Beauty Week, product trials, influencer content creation, and export consultations were combined in one space, while 111 overseas buyers from 47 countries took part, reinforcing a structure in which branding and distribution channel expansion happen simultaneously...

Local governments and the medical community are moving to expand support for postpartum recovery. Suwon’s broader postpartum support shows a trend toward incorporating Korean medicine treatment into birth-friendly policy, and in practice, a safety study tracking 186 postpartum women, though limited, is helping strengthen the evidence for its use... By contrast, stricter standards are being applied to cost control and the appropriiateness of coverage. Auto insurance medical expenses swelled to 1.5057 trillion won, fueling controversy over the overuse of Korean medicine treatment, and courts also made clear the boundaries of institutional reimbursement by refusing to recognize National Health Insurance claims for herbal preparations sold without a prescription...

Recent moves by health authorities and audit agencies are converging on strengthening verification systems rather than simply expanding technology adoption. The Ministry of Food and Drug Safety’s certification for outstanding AI digital medical device companies grants review privileges to firms with proven development capabilities while still requiring them to demonstrate post-market validity, and criticisms over duplicate construction and poor quality of public AI training data reflect the same trend. This shift reflects a growing view that as industries expand rapidly, the reliability of data and clinical operations forms the foundation of competitiveness. Going forward, speed alone in launching technology will be less of a differentiator, while companies with standardized data management and strong clinical quality assurance are likely to gain an advantage in regulatory response and business expansion.

Evidence is growing that menopause should be treated not as the point when uncomfortable symptoms begin, but as a turning point that shapes the risk of chronic disease over the following decades. Data tracking more than 5,000 women aged 42 to 52 in a national cohort show that metabolic changes begin not after menopause, but during the transition period when menstrual cycles first become irregular. This also suggests that an approach focused only on individual symptoms in women’s health has reached its limits. Cardiovascular disease in women more often involves microvascular abnormalities and may appear without typical chest pain; related research found microvascular dysfunction in 46% of women and 31% of men, underscoring the need for early recognition and sex-specific evaluation.

Research institutions are introducing propagation and cultivation technologies to change the supply structure of medicinal plants that have long depended on imports or wild harvesting. Aristolochia contorta, the source plant of Asarum, now has a stable tissue-culture propagation method, and pretreatment technology has also been proposed to improve the growth of Artemisia annua and the productivity of the key ingredient used in antimalarial treatment. This trend goes beyond simply accumulating research results; it reflects growing recognition that unstable raw material procurement has become a bottleneck for the broader bio and traditional Korean medicine industries. If cultivation can be standardized and alternative production methods established, it would reduce overharvesting of rare resources while supplying industrial raw materials with consistent quality, easing the long-standing conflict between conservation and commercialization.

Health functional foods are increasingly becoming everyday consumer goods chosen in small quantities at nearby stores and familiar platforms, rather than products people go out of their way to buy at specialty retailers. Convenience stores’ low-priced, small-pack products have sold quickly, pushing cumulative sales past 1.3 million units, while some companies have even decided to shut down their own online malls as of September 4 and shift sales toward external distribution networks. This trend is being driven by the expansion of health management from regular purchases by middle-aged consumers to more frequent, casual purchases by younger consumers. Wellness consumption has spread especially among those aged 15 to 24, and as spending on general-purpose health functional foods declines while demand for purpose-specific ingredients rises, distributors are emphasizing accessibility and ease of choice over price.